Company News

Share this article:
Bristol, Tennessee-based Graceway Pharmaceuticals announced an agreement with Pfizer to acquire worldwide commercial rights for three investigational dermatological molecules. Two of the molecules will potentially treat oily skin and acne; both are in phase 2 of development. The third molecule, an ALK-5 inhibitor, is in pre-clinical development and would reduce surgical and traumatic scar formation. Financial terms of the deal were not disclosed.

Euro RSCG acquired Medicom Group, a UK-based medical communications agency. Medicom employs roughly 20, according to the company's LinkedIn profile.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.